Newsroom | 5022 results

DUBLIN--(BUSINESS WIRE)--The "GLP-1 Analogues Market" report has been added to ResearchAndMarkets.com's offering. This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for GLP-1 analogues, with data from 2024, estimates from 2025, projections of compound annual growth rates (CAGRs) through 2030 (the forecast period 2025-2030) and regional markets for GLP-1 analogues. This report highlights the current and future market potential of GLP...

LONDON--(BUSINESS WIRE)--Automata, the lab automation company building fully integrated, AI-ready platforms for life sciences, today announced the close of a $45 million Series C funding round led by Dimension with participation from Danaher Ventures, Tru Arrow Partners, Octopus Ventures, Entrepreneurs First, and others. The round also includes a strategic investment partnership with Danaher Corporation, with Murali Venkatesan Ph.D., Global Head of Danaher Ventures and Vice President of Science...

ROCK HILL, S.C.--(BUSINESS WIRE)--Vynleads launches DWX Lifestyle Blueprint™ Technology Platform, an AI-powered health coach transforming wellness into structured routines....

AUSTIN, Texas--(BUSINESS WIRE)--Texicare, the health affiliate of Texas Mutual, is partnering with Virta Health, the leader in reversing metabolic disease, to expand care options for Texas small business employees. Through the collaboration, Texicare members gain access to Virta's virtual clinic programs for Type 2 diabetes reversal at no additional cost. One in eight Texas adults has been diagnosed with diabetes—part of a nationwide epidemic affecting over 38 million Americans. Clinical resear...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that Moody’s Ratings (Moody’s) has recently upgraded the ratings of AdaptHealth, LLC, including the Corporate Family Rating to Ba2 from Ba3 and the senior unsecured notes rating to Ba3 from B1. “Moody’s Ratings’ upgrade follows...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zag Bio™, Inc., a biotechnology company pioneering thymus-targeted medicines, today announced the appointment of Jan Hillson, M.D., a physician-scientist and rheumatologist with over 20 years of clinical development experience in autoimmune and inflammatory diseases across early and late stages, as Chief Medical Officer. Dr. Hillson will oversee Zag’s clinical development strategy and execution and guide pipeline advancement. She will lead Zag’s clinical team...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will hold a conference call to review the company's fourth quarter and fiscal year 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations webs...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estim...

ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has agreed to INTENT’s Initial Pediatric Study Plan (iPSP) for PEP Biologic™ under IND 019567, supporting the company’s request for a full pediatric waiver for its forthcoming Biologics License Applicati...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Soley Announces Breakthrough Research Demonstrating How Cellular Stress Responses Reveal Drug Mechanisms, Enabling New Methods for Drug Discovery...